<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03147261</url>
  </required_header>
  <id_info>
    <org_study_id>UNavarre</org_study_id>
    <nct_id>NCT03147261</nct_id>
  </id_info>
  <brief_title>Impact of Comprehensive Intervention on the Cardiometabolic Risk in Children With Central Obesity (IGENOI)Obesity</brief_title>
  <acronym>IGENOI</acronym>
  <official_title>Impacto de Una intervención Integral Sobre el Riesgo cardiometabólico en niños Con Obesidad Central: Estudio de Marcadores genéticos y epigenéticos</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Navarra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Central obesity, present in the metabolic syndrome (MS), is associated with increased risk of&#xD;
      insulin resistance (RI). The aim of the project is to evaluate the protective effect of&#xD;
      comprehensive intervention (Mediterranean diet + physical activity) in the development of RI&#xD;
      in children with central obesity based on genetic and epigenetic markers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives: 1) Apply a comprehensive therapeutic nutrition intervention program for&#xD;
      monitoring the Mediterranean Diet (DM) slightly hypocaloric along with increased physical&#xD;
      activity in children with central obesity 7-16 years). 2) Measure the effectiveness of this&#xD;
      program by assessing changes in body composition, lifestyle and biological and molecular&#xD;
      parameters (genetic and epigenetic).&#xD;
&#xD;
      Methodology: test randomized, longitudinal, controlled, two-year intervention field comparing&#xD;
      a sample of 120 subjects from 7 to 16 years with central obesity, the effect of two&#xD;
      interventions: a) intensive on lifestyle with a reduced calorie DM , physical activity and&#xD;
      behavioral therapy, b) non-intensive with healthy diet recommendations following the usual&#xD;
      pediatric advice. At 2, 6, 12 and 24 months after follow up changes will be assessed: a) the&#xD;
      HOMA index, body fat, and the cardiovascular risk factors, b) diet, sleep patterns, physical&#xD;
      exercise using questionnaires and accelerometers (intervention group), and c) the quality of&#xD;
      life. genetic and epigenetic markers will be evaluated by genotyping SNPs genes related to&#xD;
      RI; and the analysis of: a) DNA methylation in genes related to insulin resistance, b)&#xD;
      expression of microRNAs and target genes related to insulin resistance and c) measure the&#xD;
      length of telomeres. The therapeutic program will consist of individual sessions and group&#xD;
      workshops for the patient and the family.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in the HOMA index</measure>
    <time_frame>At 2, 6, 12 and 24 months after follow up</time_frame>
    <description>changes will be assessed in the HOMA index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>genetic and epigenetic markers will be evaluated</measure>
    <time_frame>At 2, 6, 12 and 24 months after follow up</time_frame>
    <description>genetic and epigenetic markers will be evaluated by genotyping SNPs genes related to RI; and the analysis of: a) DNA methylation in genes related to insulin resistance, b) expression of microRNAs and target genes related to insulin resistance and c) measure the length of telomeres</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Pediatric Obesity</condition>
  <arm_group>
    <arm_group_label>lifestyle intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensive follow up in lifestyle factors with a reduced calorie DM , physical activity and behavioural therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy diet recommendations following the usual pediatric advice</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lifestyle intervention</intervention_name>
    <description>Intensive changes in lifestyle with a reduced calorie mediterranean diet, physical activity and behavioral therapy</description>
    <arm_group_label>lifestyle intervention</arm_group_label>
    <other_name>No intervention</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Signed informed consent by the child, parent or guardian. 3. waist circumference above&#xD;
        the 90th percentile 4. Motivation and willingness to be assigned to either group, and do&#xD;
        their utmost to follow protocol assigned.&#xD;
&#xD;
        5. Possibility of involvement in days of intensive phase (week 0, 1, 2, 3, 4, 5, 6, 7 and&#xD;
        8) and once a month until 6 months later at 4 months and every 6 months during the second&#xD;
        year.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pre-Diabetes&#xD;
&#xD;
          2. Presence of other diseases&#xD;
&#xD;
          3. Pharmacotherapy&#xD;
&#xD;
          4. Monitoring special diets&#xD;
&#xD;
          5. Food intolerance&#xD;
&#xD;
          6. Regular alcohol consumption&#xD;
&#xD;
          7. Drug&#xD;
&#xD;
          8. Psychiatric illness or eating disorder&#xD;
&#xD;
          9. People without telephone or Internet access&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amelia Marti, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Navarra</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNavarre</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 3, 2017</study_first_submitted>
  <study_first_submitted_qc>May 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2017</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Pediatric Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

